We’ll be conducting routine maintenance on Saturday, August 3rd.
Our phone system will be unavailable during this time, but you’ll be able to chat with our live agents 24/7 or you can email Support.

GLP-1 Access and Transparency

Our commitment to safe, responsible GLP-1 care

At Noom, we believe behavior is essential to lasting change.

GLP-1s are one of the most powerful tools in modern medicine — offering benefits that may extend beyond weight loss to better metabolic health, cardiovascular function, inflammation reduction, sleep, and perhaps even mood.1

That’s why Noom built a powerful GLP-1 Companion app. Most people will eventually stop taking a GLP-1. What lasts are habits and identity. At Noom, we incorporate GLP-1 into an integrated program for behavior change. We use GLP-1s not as a band-aid, but as a bridge.

Why GLP-1s Matter Now

Obesity and metabolic disease are at the heart of today’s global health crisis. GLP-1 receptor agonists have changed the way clinicians can address these conditions — helping millions lose weight and improve metabolic health.

Yet too often, GLP-1s are prescribed as a quick fix. At Noom, we see their full potential: as a way to restore metabolic balance, enhance long-term health, and empower sustainable habit change.

70%

have obesity or are overweight2

25%

will have severe obesity by 20303

50%

are interested in weight-loss drugs4

Our Commitment to Responsible GLP-1 Care

Noom’s medical programs are designed and led by clinicians who share a safety-first philosophy.

How We Think About Safety & Quality

Noom is committed to safety and quality. We partner with U.S. Pharmacopeia (USP)-compliant, state-regulated pharmacies for plans that include medication, and only source active pharmaceutical ingredients from suppliers on the FDA green list.

USP Regulations

Noom has carefully selected pharmacy partners that are held to strict standards to ensure quality and compliance. They are regulated by State Boards of Pharmacy and must adhere to USP guidelines.

Quality Assurance

Noom’s pharmacy partners feature state-of-the-art equipment and purchase all raw materials from FDA-registered facilities. Every batch is thoroughly tested by a third-party testing facility.

Certificate of Analysis (COA)

Noom Med provides utmost transparency as to the ingredients and quality of each batch of medication. Noom GLP-1Rx Program patients may request a COA from their care coordination team (careteam@noom.com). A COA is a document provided by the pharmacy, which shows the active medication ingredient meets regulatory requirements.

Our Clinical Protocol

Our clinicians developed a robust clinical protocol for the Noom GLP-1Rx Program. Experienced telehealth and obesity physicians support access-maximizing asynchronous care pathways and evidence-based lab flows. In some programs, synchronous video visits are also available.

We leverage multiple modalities to ensure patients receive timely, patient-centered, and effective treatment.

That said, we believe in the benefits of appropriately used asynchronous care, which include:

Accessibility
Patient wait times for care are reduced from days to hours, and patients can conveniently access a doctor via chat

Reduced Cost
Highly efficient workflows reduce physician time on each consult

Access to Treatment Plans
Patients can easily refer to the asynchronous chat log with their clinician to review the discussion

Quality
Clinical supervisors can review transcripts to ensure clinician quality

Patient and Clinician Experience
Administrative staff can be automatically alerted to and more easily resolve missing intake information and other administrative issues that often cause synchronous visits to be delayed, canceled, or rescheduled

Privacy & De-stigmatization
Due to the stigma of obesity, patients may feel more comfortable discussing sensitive health issues through asynchronous communication, as it provides a layer of privacy

 

Our intake process:

We verify the identity of every patient.

We require a full body photo before treatment.

We require a comprehensive medical intake.

Noom’s Commitment to Addressing the Individual Needs of Patients

The most trusted obesity care guidelines recommend that GLP-1s be used in combination with a reduced calorie diet and increased physical activity for best results. But very few healthcare providers are able to support GLP-1 patients in making these crucial changes.

The latest data also shows that most people stop taking GLP-1s within 12 months and experience significant side effects throughout treatment.5

These factors can lead to reduced weight loss and fewer health benefits from treatment.

71%

stop taking GLP-1s by 12 months6

74%

report gastrointestinal symptoms7

65%

report NO increased exercise after starting medication8

This is why the Noom GLP-1Rx Program with Noom GLP-1 Companion exists. Noom responds to patients’ unique needs through proven medical and behavioral interventions that help them maximize the benefits of GLP-1 medication—and get weight-loss results that last.

Medication Alone is Not Enough.

Most people will stop taking the GLP-1 eventually. Behavior change must occur alongside the medication for sustained success.

Without a companion program, it’s possible to end up with sarcopenic obesity and a higher body fat composition than before starting the meds—up to 40% of weight loss can be muscle.9

Behavior change combined with GLP-1s drives lasting weight loss.10

Without behavior change, most of the lost weight will come back within 12 months of stopping the medication.

Behavior Change Group Better Maintains Weight Loss11

6 out of 7 people stop taking GLP-1s12.

Most people will stop taking their GLP-1 eventually. Behavior change must occur alongside the medication for sustained success.

Noom Med’s GLP-1Rx Program: A Personalized, Integrated Solution

Every step of the GLP-1 journey is built on trust and rigor.

  1. We prescribe generic, compounded, and brand name medications
  2. Comprehensive intake before prescribing
  3. SmartDoseTM titration for gradual, personalized dosing
  4. Ongoing clinical monitoring and side-effect management
  5. Continuous behavioral support through the Noom platform

Noom Microdose GLP-1Rx Program: Low Doses Produce Meaningful Weight-Loss.

Our tiered dosing philosophy ensures each member gets the right level for their biology and goals:

Microdose

Gentle, steady, minimum dosing

Standard

Optimized for metabolic improvement and weight reduction

Maintenance

Long-term stabilization for sustained result

Our own data shows members achieve up to 11 pounds lost in 60 days at microdose levels – demonstrating clinically meaningful impact. Third-party researchers combining lower doses with behavior change are seeing similar impact. A 2,700-person study out of Denmark saw an average of 16% body weight loss at 64 weeks for the 20% of the participants who remained at microdose levels for the duration of the study.

GLP-1 therapy has been linked to improved inflammatory markers (like Hs-CRP), metabolic markers (like HbA1C), and lipid/cholesterol markers (like HDL and LDL).13

11 lbs

Weight lost in 60 days by members in the top 25th percentile on a GLP-1 microdose dosage11

2x

Members engaged with the Noom app on a GLP-1Rx plan achieve 10% weight loss by month four at twice the rate of those not engaged

Longevity Benefits Beyond Weight Loss?

GLP-1s are one of the most powerful drug classes in modern medicine. Recent studies show their benefits may go beyond weight loss to blood sugar regulation, cardiovascular health, reduced inflammation, better sleep, and perhaps even improved mood.15

“The latest science demonstrates that we should be thinking about GLP-1 medication differently. GLP-1s may no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.”

Dr. Jeffrey Egler, Chief Medical Officer at Noom.

Powerful GLP-1 Companion

Noom is more than meds. Our powerful and engaging GLP-1 Companion is the true star of our programs.

Keep the muscle, lose the fat

Muscle Defense mobile screen

Develop healthy habits

lesson mobile screen

Find support in community

community mobile screen

Ask your 1:1 coach anything

Chat mobile screen

Leadership and Advocacy

Noom is setting the standard for ethical, evidence-based GLP-1 care. We publish our definitions, share our data, and collaborate with leading researchers to move the field forward.

“GLP-1s are not a shortcut — they’re a scientific breakthrough that demands care, precision, and context,” said Dr. Jeffrey Egler. “Our responsibility is to ensure people use these medications safely, sustainably, and successfully.”

Noom Clinical Leadership

andrew gostine

Jeffrey Egler

Chief Medical Officer
Dr. Jeffrey Egler, MD, is a double board-certified physician in Family Medicine and Lifestyle Medicine. After completing an academic medicine fellowship in Faculty Development at UCLA, Dr. Egler went on to practice the full spectrum of family medicine (including adult medicine, pediatrics, surgery, emergency and hospital medicine, and obstetrics and gynecology) and subsequently became an Assistant Clinical Professor of Family Medicine at USC.

He obtained a master’s degree in Spiritual Psychology and completed certification training with the Institute of Functional Medicine and the American College of Lifestyle Medicine. He was the founding Medical Director of Parsley Health in Los Angeles and later of the Inspire Health Center, a wellness center at the Adventist Health corporate headquarters. He most recently had been practicing Longevity Medicine, the ultimate culmination of these arts and sciences, as the Medical Director of Next Health in Los Angeles.

andrew gostine

Julia Edelman

Executive Director of Women’s Health

Julia Schlam Edelman, MD is a gynecologist, author, and public speaker. An expert in menopause and women’s health, Dr. Edelman has written two books for patients and their physicians: Menopause Matters: Your Guide to a Long and Healthy Life (Johns Hopkins University Press) and Successful Sleep Strategies for Women (Harvard Health Publications).

After earning a BS from Yale, and an MD at Columbia University’s College of Physicians and Surgeons, Dr. Edelman completed an OB-GYN residency at Brigham and Women’s Hospital. Dr. Edelman has taught at both Harvard and Brown University Medical Schools, and served as a clinical consultant at the Massachusetts General Hospital. She served on the Board of Trustees of the Massachusetts Medical Society for ten years. Massachusetts Medical Society selected Dr. Edelman as their Clinician of the Year in 2018.

Dr. Edelman has operated a solo, private practice in Southeastern Massachusetts for over 25 years. Named “Menopause Clinician of the Year” by The North American Menopause Society in 2010, Dr. Edelman enjoys speaking with women about the latest developments in women’s health. Her new book The Savvy Woman’s Guide to Menopause: Before, During, and Beyond will be published by Johns Hopkins University Press in 2025.

andrew gostine

Karen Mann

Medical Director

Dr. Karen Mann is a board-certified OB-GYN who received her medical degree from The George Washington University School of Medicine and completed her residency at Kaiser Permanente, Los Angeles Medical Center.

She also holds a BA in Sociology from UCLA, graduating Summa Cum Laude. With over a decade of experience in caring for women, her focus has been on family planning at FPA Women’s Health in California, where she also led the “Weigh to Wellness” weight-loss program, managed their prenatal program, and spearheaded their telehealth platform, which has been running for over five years. Dr. Mann is a diplomate of the American Board of Obesity Medicine and a certified menopause practitioner (MSCP) through The Menopause Society.

Committed to ongoing education, she has studied nutrition science at Stanford and integrative nutrition through the Integrative and Functional Nutrition Academy. She became a certified life coach and strives to incorporate mindfulness-based stress reduction and trauma-informed care into her practice, living her mission of empowering individuals to achieve their health goals through a compassionate and holistic approach.

andrew gostine

Yalda Olcott

Head of Healthcare Operations

Yalda holds a Doctor of Pharmacy degree from North Dakota State University and brings over a decade of pharmacy leadership experience, including retail pharmacy, medication therapy management (MTM), and pharmacy benefits management (PBM).

Ms. Olcott’s extensive PBM experience includes utilization management, formulary development, clinical program development, and maintaining client relationships.

Most recently, Ms. Olcott held the role of VP Operations and Account Services at ClearScript. In this role, she led oversight and strategy of clinical programs, clinical services, product development, client relationships, and vendor management. At Prime Therapeutics, she held many leadership roles, was heavily involved in utilization management and medication therapy management, and maintained client relationships while delivering cost-effective solutions for employers and health plans.

Noom Science Advisory Board

lindsey connors

Lindsey Connors

Lindsey Connors, Pharm.D is a highly skilled pharmacist with a diverse focus including long-term care, compounding pharmacy, consulting, clinical research, and technical writing.

Lindsey received specialized training in sterile compounding from Critical Point and has honed her skills through extensive experience in busy 503a compounding pharmacies. Lindsey has developed regulatory-compliant quality systems tailored for smaller pharmacies and has guided clients through the complexities of regulatory agencies such as the NABP, FDA, and various state boards of pharmacies. Her expertise extends to managing teams of professionals and support staff while overseeing the fiscal management of pharmacy operations. Known for her ability to build cohesive teams by balancing diverse perspectives and working towards shared objectives, Lindsey is licensed in Alabama, Florida, Illinois, Maryland, Michigan, Oklahoma, Texas, and Virginia.

Pouran Faghri

Dr. Pouran Faghri is an Adjunct Full Professor in the Department of Environmental Health Sciences at the Fielding School of Public Health, University of California, Los Angeles.

As a pioneer in behavioral interventions for weight loss and maintenance, Dr. Faghri’s work includes the application of cognitive-behavioral techniques and social support to improve self-regulation, enhance self-efficacy, and increase self-control. She has also employed strategies from behavioral economics and contingency management for effective weight management. As an occupational health expert, Dr. Faghri’s comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes. A sought-after speaker at national and international conferences, she shares insights on public health advancements and strategies for promoting healthy living.

andrew gostine

Andrew Gostine

Andrew Gostine, MD, MBA, is an accomplished healthcare professional, passionate about leveraging artificial intelligence in the clinical setting.

As a co-founder and the CEO of Artisight, he is at the forefront of fusing deep learning and IoT sensors to facilitate healthcare automation and optimization.

Dr. Gostine’s journey began as a critical care anesthesiologist, where he gained valuable insights into the evolving needs of practicing clinicians in the ICUs and operating rooms. This firsthand experience inspired him to establish Artisight with a vision to address real problems in hospital workflow to improve overall efficiencies.

Beyond his entrepreneurial pursuits, Dr. Gostine remains actively engaged in clinical practice. This dedication allows him to stay up-to-date with clinicians’ changing and dynamic needs, bridging the gap between technological advancements and their practical applications in healthcare.

Noom Partners in Safety

Accorded logo
  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10584355/
  2. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity
  3. https://news.harvard.edu/gazette/story/2019/12/close-to-half-of-u-s-population-projected-to-have-obesity-by-2030/
  4. https://www.kff.org/health-costs/poll-nearly-half-of-adults-would-be-interested-in-prescription-weight-loss-drugs-but-enthusiasm-fades-based-on-lack-of-coverage-and-risk-of-regaining-weight/
  5. https://www.primetherapeutics.com/w/prime-continues-to-lead-industry-on-glp-1-research-1-in-7-stays-on-glp-1-drugs-for-weight-loss-after-two-years
  6. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779?
  7. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  8. https://www.washingtonpost.com/health/2025/02/23/ozempic-wegovy-change-life-spending/?srsltid=AfmBOoqJm839h3l4aNQ_EgVPfJuj4wUNIoxzTCnpM_XMCLfOv46mkUBN
  9. https://www.techtarget.com/pharmalifesciences/answer/Addressing-muscle-loss-associated-with-GLP-1-medication-use?srsltid=AfmBOoqJm839h3l4aNQ_EgVPfJuj4wUNIoxzTCnpM_XMCLfOv46mkUBN#:~:text=%E2%80%9CAnywher%5B%25
  10. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00054-3/fulltext?srsltid=AfmBOoqJm839h3l4aNQ_EgVPfJuj4wUNIoxzTCnpM_XMCLfOv46mkUBN
  11. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00054-3/fulltext?srsltid=AfmBOoqJm839h3l4aNQ_EgVPfJuj4wUNIoxzTCnpM_XMCLfOv46mkUBN
  12. https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-stop-using-wegovy-ozempic-weight-loss-within-two-years-analysis-2024-07-10/?srsltid=AfmBOoqJm839h3l4aNQ_EgVPfJuj4wUNIoxzTCnpM_XMCLfOv46mkUBN
  13. https://pubmed.ncbi.nlm.nih.gov/38286487/
  14. Based on an analysis of self-reported data from 1,185 engaged Noom GLP-1Rx Program users with a BMI of 25 or greater.
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10584355/ – https://www.pulmonologyadvisor.com/features/glp-1-for-sleep-apnea/ – https://midtownpractice.com/the-gut-brain-connection-exploring-glp-1s-and-your-mental-well-being/